Gilead Sciences (GILD) reported $7.57 billion in income for the quarter ended December 2024, representing a year-over-year enhance of 6.4%. EPS of $1.90 for a similar interval compares to $1.72 a yr in the past.
The reported income compares to the Zacks Consensus Estimate of $7.06 billion, representing a shock of +7.27%. The corporate delivered an EPS shock of +13.77%, with the consensus EPS estimate being $1.67.
Whereas buyers scrutinize income and earnings adjustments year-over-year and the way they examine with Wall Avenue expectations to find out their subsequent transfer, some key metrics at all times provide a extra correct image of an organization’s monetary well being.
As these metrics affect top- and bottom-line efficiency, evaluating them to the year-ago numbers and what analysts estimated helps buyers venture a inventory’s worth efficiency extra precisely.
Right here is how Gilead carried out within the simply reported quarter by way of the metrics most generally monitored and projected by Wall Avenue analysts:
- Product Gross sales- Veklury- U.S. $108 million versus the three-analyst common estimate of $160.11 million. The reported quantity represents a year-over-year change of -70.3%.
- Product Gross sales- Oncology- Trodelvy- U.S. $247 million versus $237.09 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +9.3% change.
- Product Gross sales- Liver Illness- Sofosbuvir / Velpatasvir- U.S. $185 million versus $202.61 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a -14.4% change.
- Product Gross sales- HIV- Symtuza-Income share- U.S. $112 million versus the three-analyst common estimate of $109.94 million. The reported quantity represents a year-over-year change of +7.7%.
- Whole product sales- Whole: $7.54 billion versus $7.06 billion estimated by eight analysts on common. In comparison with the year-ago quarter, this quantity represents a +6.6% change.
- Revenues- Royalty contract and different revenues: $33 million versus the eight-analyst common estimate of $49.91 million. The reported quantity represents a year-over-year change of -26.7%.
- Product Gross sales- Oncology- Cell Remedy- Yescarta- Whole: $390 million versus $386.44 million estimated by seven analysts on common. In comparison with the year-ago quarter, this quantity represents a +6% change.
- Product Gross sales- HIV- Biktarvy- Whole: $3.77 billion versus the seven-analyst common estimate of $3.46 billion. The reported quantity represents a year-over-year change of +21.4%.
- Product Gross sales- HIV- Odefsey- Whole: $336 million in comparison with the $314.11 million common estimate based mostly on seven analysts. The reported quantity represents a change of -1.2% yr over yr.
- Product Gross sales- HIV- Genvoya- Whole: $470 million versus the seven-analyst common estimate of $482.51 million. The reported quantity represents a year-over-year change of -9.1%.
- Product Gross sales- HIV- Descovy- Whole: $616 million in comparison with the $573.59 million common estimate based mostly on seven analysts. The reported quantity represents a change of +21% yr over yr.
- Product Gross sales- Oncology- Trodelvy- Whole: $355 million versus the seven-analyst common estimate of $281.97 million. The reported quantity represents a year-over-year change of +18.7%.
View all Key Company Metrics for Gilead here>>>
Shares of Gilead have returned +6.2% over the previous month versus the Zacks S&P 500 composite’s +4.2% change. The inventory presently has a Zacks Rank #3 (Maintain), indicating that it might carry out according to the broader market within the close to time period.
Solely $1 to See All Zacks’ Buys and Sells
We’re not kidding.
A number of years in the past, we shocked our members by providing them 30-day entry to all our picks for the whole sum of solely $1. No obligation to spend one other cent.
1000’s have taken benefit of this chance. 1000’s didn’t – they thought there have to be a catch. Sure, we do have a cause. We wish you to get acquainted with our portfolio companies like Shock Dealer, Shares Underneath $10, Know-how Innovators,and extra, that closed 256 positions with double- and triple-digit beneficial properties in 2024 alone.
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
